1921
Volume 100, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

18S rRNA is a biomarker that provides an alternative to thick blood smears in controlled human malaria infection (CHMI) trials. We reviewed data from CHMI trials at non-endemic sites that used blood smears and 18S rRNA/rDNA biomarker nucleic acid tests (NATs) for time to positivity. We validated a multiplex quantitative reverse transcription–polymerase chain reaction (qRT-PCR) for 18S rRNA, prospectively compared blood smears and qRT-PCR for three trials, and modeled treatment effects at different biomarker-defined parasite densities to assess the impact on infection detection, symptom reduction, and measured intervention efficacy. Literature review demonstrated accelerated NAT-based infection detection compared with blood smears (mean acceleration: 3.2–3.6 days). For prospectively tested trials, the validated 18S rRNA qRT-PCR positivity was earlier (7.6 days; 95% CI: 7.1–8.1 days) than blood smears (11.0 days; 95% CI: 10.3–11.8 days) and significantly preceded the onset of grade 2 malaria-related symptoms (12.2 days; 95% CI: 10.6–13.3 days). Discrepant analysis showed that the risk of a blood smear–positive, biomarker-negative result was negligible. Data modeling predicted that treatment triggered by specific biomarker-defined thresholds can differentiate complete, partial, and non-protective outcomes and eliminate many grade 2 and most grade 3 malaria-related symptoms post-CHMI. 18S rRNA is a sensitive and specific biomarker that can justifiably replace blood smears for infection detection in CHMI trials in non-endemic settings. This study led to biomarker qualification through the U.S. Food and Drug Administration for use in CHMI studies at non-endemic sites, which will facilitate biomarker use for the qualified context of use in drug and vaccine trials.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.19-0094
2019-06-05
2019-07-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/100/6/tpmd190094.html?itemId=/content/journals/10.4269/ajtmh.19-0094&mimeType=html&fmt=ahah

References

  1. WHO, 2018. World Malaria Report 2018. Geneva, Switzerland: World Health Organization. [Google Scholar]
  2. Laurens MB, Consensus Group on Design of Clinical Trials of Controlled Human Malaria Infection , 2012. A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines. Vaccine 30: 53025304. [Google Scholar]
  3. Bruce-Chwatt LJ, , 1984. DNA probes for malaria diagnosis. Lancet 1: 795. [Google Scholar]
  4. Payne D, , 1988. Use and limitations of light microscopy for diagnosing malaria at the primary health care level. Bull World Health Organ 66: 621626. [Google Scholar]
  5. Murphy SC, Shott JP, Parikh S, Etter P, Prescott WR, Stewart VA, , 2013. Malaria diagnostics in clinical trials. Am J Trop Med Hyg 89: 824839. [Google Scholar]
  6. Roth JM, Korevaar DA, Leeflang MM, Mens PF, , 2016. Molecular malaria diagnostics: a systematic review and meta-analysis. Crit Rev Clin Lab Sci 53: 87105. [Google Scholar]
  7. Gunderson JH, Sogin ML, Wollett G, Hollingdale M, de la Cruz VF, Waters AP, McCutchan TF, , 1987. Structurally distinct, stage-specific ribosomes occur in Plasmodium. Science 238: 933937. [Google Scholar]
  8. Waters AP, Syin C, McCutchan TF, , 1989. Developmental regulation of stage-specific ribosome populations in Plasmodium. Nature 342: 438440. [Google Scholar]
  9. Li J, McConkey GA, Rogers MJ, Waters AP, McCutchan TR, , 1994. Plasmodium: the developmentally regulated ribosome. Exp Parasitol 78: 437441. [Google Scholar]
  10. Murphy SC, 2012. Real-time quantitative reverse transcription PCR for monitoring of blood-stage Plasmodium falciparum infections in malaria human challenge trials. Am J Trop Med Hyg 86: 383394. [Google Scholar]
  11. Murphy SC, Daza G, Chang M, Coombs R, , 2012. Laser cutting eliminates nucleic acid cross-contamination in dried-blood-spot processing. J Clin Microbiol 50: 41284130. [Google Scholar]
  12. Schneider P, Wolters L, Schoone G, Schallig H, Sillekens P, Hermsen R, Sauerwein R, , 2005. Real-time nucleic acid sequence-based amplification is more convenient than real-time PCR for quantification of Plasmodium falciparum. J Clin Microbiol 43: 402405. [Google Scholar]
  13. Hodgson SH, 2015. Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies. Malar J 14: 33. [Google Scholar]
  14. Lyke KE, 2017. Attenuated PfSPZ vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci USA 114: 27112716. [Google Scholar]
  15. Murphy SC, 2018. A randomized trial evaluating the prophylactic activity of DSM265 against preerythrocytic Plasmodium falciparum infection during controlled human malarial infection by mosquito bites and direct venous inoculation. J Infect Dis 217: 693702. [Google Scholar]
  16. Ishizuka AS, 2016. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med 22: 614623. [Google Scholar]
  17. Murphy JR, Baqar S, Davis JR, Herrington DA, Clyde DF, , 1989. Evidence for a 6.5-day minimum exoerythrocytic cycle for Plasmodium falciparum in humans and confirmation that immunization with a synthetic peptide representative of a region of the circumsporozoite protein retards infection. J Clin Microbiol 27: 14341437. [Google Scholar]
  18. Fairley NH, , 1947. Sidelights on malaria in man obtained by subinoculation experiments. Trans R Soc Trop Med Hyg 40: 621676. [Google Scholar]
  19. Hodgson SH, 2014. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front Microbiol 5: 686. [Google Scholar]
  20. Mordmuller B, 2015. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar J 14: 117. [Google Scholar]
  21. Talley AK, 2014. Safety and comparability of controlled human Plasmodium falciparum infection by mosquito bite in malaria-naive subjects at a new facility for sporozoite challenge. PLoS One 9: e109654. [Google Scholar]
  22. Sheehy SH, 2012. Chad63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther 20: 23552368. [Google Scholar]
  23. Lyke KE, 2010. Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial. PLoS One 5: e13490. [Google Scholar]
  24. Leptak C, 2017. What evidence do we need for biomarker qualification? Sci Transl Med 9: eaal4599. [Google Scholar]
  25. Westgard JO, , 2016. Basic Quality Control Practices, 4th edition. Westgard Quality Corporation. [Google Scholar]
  26. FDA, 2007. Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests. FDA Center for Devices and Radiological Health. [Google Scholar]
  27. CLSI, 2009. User Protocol for Evaluation of Qualitative Test Performance, EP12-A2, 2nd edition. [Google Scholar]
  28. Adams M, 2015. An ultrasensitive reverse transcription polymerase chain reaction assay to detect asymptomatic low-density Plasmodium falciparum and Plasmodium vivax infections in small volume blood samples. Malar J 14: 520. [Google Scholar]
  29. Seder RA, VRC 312 Study Team , 2013. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341: 13591365. [Google Scholar]
  30. Mordmuller B, 2017. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542: 445449. [Google Scholar]
  31. Roestenberg M, 2013. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 88: 513. [Google Scholar]
  32. Verhage DF, Telgt DS, Bousema JT, Hermsen CC, van Gemert GJ, van der Meer JW, Sauerwein RW, , 2005. Clinical outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes. Neth J Med 63: 5258. [Google Scholar]
  33. Thompson FM, 2008. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One 3: e1493. [Google Scholar]
  34. Spring MD, 2009. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS One 4: e5254. [Google Scholar]
  35. Roestenberg M, 2009. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 361: 468477. [Google Scholar]
  36. Roestenberg M, 2011. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 377: 17701776. [Google Scholar]
  37. Epstein JE, 2011. Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 334: 475480. [Google Scholar]
  38. Roestenberg M, O’Hara GA, Duncan CJ, Epstein JE, Edwards NJ, Scholzen A, van der Ven AJ, Hermsen CC, Hill AV, Sauerwein RW, , 2012. Comparison of clinical and parasitological data from controlled human malaria infection trials. PLoS One 7: e38434. [Google Scholar]
  39. Chuang I, 2013. DNA prime/adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 8: e55571. [Google Scholar]
  40. Laurens MB, 2013. Successful human infection with P. falciparum using three aseptic Anopheles stephensi mosquitoes: a new model for controlled human malaria infection. PLoS One 8: e68969. [Google Scholar]
  41. Kamau E, Alemayehu S, Feghali KC, Komisar J, Regules J, Cowden J, Ockenhouse CF, , 2014. Measurement of parasitological data by quantitative real-time PCR from controlled human malaria infection trials at the Walter Reed Army Institute of Research. Malar J 13: 288. [Google Scholar]
  42. Hodgson SH, 2015. Evaluation of the efficacy of Chad63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis 211: 10761086. [Google Scholar]
  43. Gomez-Perez GP, 2015. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates. Malar J 14: 306. [Google Scholar]
  44. Bastiaens GJ, 2016. Safety, immunogenicity, and protective efficacy of intradermal immunization with aseptic, purified, cryopreserved Plasmodium falciparum sporozoites in volunteers under chloroquine prophylaxis: a randomized controlled trial. Am J Trop Med Hyg 94: 663673. [Google Scholar]
  45. Sulyok M, 2017. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. Lancet Infect Dis 17: 636644. [Google Scholar]
  46. CLSI, 2008. Validation and Verification of Multiplex Nucleic Acid Assays, MM17, 2nd edition. Wayne, PA: Clinical and Laboratory Standards Institute. [Google Scholar]
  47. Murphy SC, 2014. External quality assurance of malaria nucleic acid testing for clinical trials and eradication surveillance. PLoS One 9: e97398. [Google Scholar]
  48. Chesher D, , 2008. Evaluating assay precision. Clin Biochem Rev 29 (Suppl 1): S23S26. [Google Scholar]
  49. CLSI, 2012. Protocols for Determination of Limits of Detection and Limits of Quantitation, EP17-A2, 2nd edition. [Google Scholar]
  50. Hanron AE, Billman ZP, Seilie AM, Chang M, Murphy SC, , 2017. Detection of Babesia microti parasites by highly sensitive 18S rRNA reverse transcription PCR. Diagn Microbiol Infect Dis 87: 226228. [Google Scholar]
  51. FDA, 2018. Qualified Biomarkers and Supporting Information (CDER Biomarker Qualification Program). Available at: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/BiomarkerQualificationProgram/ucm535383.htm . Accessed March 19, 2019. [Google Scholar]
  52. Coffeng LE, Hermsen CC, Sauerwein RW, de Vlas SJ, , 2017. The power of malaria vaccine trials using controlled human malaria infection. PLoS Comput Biol 13: e1005255. [Google Scholar]
  53. Lell B, 2018. Impact of sickle cell trait and naturally acquired immunity on uncomplicated malaria after controlled human malaria infection in adults in Gabon. Am J Trop Med Hyg 98: 508515. [Google Scholar]
  54. Amur SG, Sanyal S, Chakravarty AG, Noone MH, Kaiser J, McCune S, Buckman-Garner SY, , 2015. Building a roadmap to biomarker qualification: challenges and opportunities. Biomark Med 9: 10951105. [Google Scholar]
  55. Amur S, LaVange L, Zineh I, Buckman-Garner S, Woodcock J, , 2015. Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization. Clin Pharmacol Ther 98: 3446. [Google Scholar]
  56. Burkot TR, Williams JL, Schneider I, , 1984. Infectivity to mosquitoes of Plasmodium falciparum clones grown in vitro from the same isolate. Trans R Soc Trop Med Hyg 78: 339341. [Google Scholar]
  57. Teirlinck AC, 2013. NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections. J Infect Dis 207: 656660. [Google Scholar]
  58. Langenberg MCC, 2018. Controlled human malaria infection with graded numbers of Plasmodium falciparum NF135.C10- or NF166.C8-infected mosquitoes. Am J Trop Med Hyg 99: 709712. [Google Scholar]
  59. Schats R, 2015. Heterologous protection against malaria after immunization with Plasmodium falciparum sporozoites. PLoS One 10: e0124243. [Google Scholar]
  60. Friedman-Klabanoff DJ, Laurens MB, Berry AA, Travassos MA, Adams M, Strauss KA, Shrestha B, Levine MM, Edelman R, Lyke KE, , 2019. The controlled human malaria infection experience at the University of Maryland. Am J Trop Med Hyg 100: 556565. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.19-0094
Loading
/content/journals/10.4269/ajtmh.19-0094
Loading

Data & Media loading...

Supplemental information, tables, and figures

  • Received : 30 Jan 2019
  • Accepted : 21 Mar 2019
  • Published online : 05 Jun 2019

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error